Seminars in Oncology
Volume 33, Issue 1 , Pages 74-85 , February 2006

Myelotoxicity From Chemotherapy

  • Davey Daniel

      Affiliations

    • Department of Hematology-Medical Oncology, Duke University Medical Center, Durham, NC
    • ,
  • Jeffrey Crawford

      Affiliations

    • Department of of Medical Oncology, Duke University Medical Center, Durham, NC
    • Corresponding Author InformationAddress correspondence to Jeffrey Crawford, MD, Duke University Medical Center, Box 3198 Morris Building, Room 25178, Durham, NC 27710

References 

  1. Lyman GH , Kuderer NM , Agboola O , et al.   The epidemiology and economics of neutropenia in hospitalized cancer patients (Data from the University Health System Consortium) . Blood . 2001;98(suppl):432a; (pt. 1, abstr 1813)
  2. Chrischilles EA , Link B , Scott S , et al.   Factors associated with early termination of CHOP, and its association with oveall survival among patients with intermediate-grade non-Hodgkin’s lymphoma (NHL) . Proc Am Soc Clin Oncol . 2002;21:143a; (abstr 1539)
  3. Wilson-Royalty M , Lawless G , Palmer C , et al.   Predictors for chemotherapy-related severe of febrile neutropenia (A review of the clinical literature) . J Oncol Pharm Pract . 2002;7:141–147
  4. Lyman GH , Delgado DJ . Risk and timing of hospitalization among patients receiving CHOP-like regimens for intermediate-grade non-Hodgkin’s lymphoma . Blood . 2002;100(suppl):780a; (pt. 1, abstr)
  5. Bodey GP , Buckley M , Sathe YS , et al.   Quantitative relationships between circulating leukocytes and infection in patients with acute leukemia . Ann Intern Med . 1966;64:328–340
  6. Blackwell S , Crawford J . Filgrastim (rmetHuG-CSF) in the chemotherapy setting . In:  Morsty G ,  Dexter TM editor. Filgrastim (r-metuG-CSF) in Clinical Practice . New York, NY: Marcel Dekker; 1994;p. 103–116
  7. Talcott JA , Finberg R , Bayer RJ , et al.   The medical course of cancer patients with fever ad neutropenia. Clinical identification of a low-risk subgroup at presentation . Arch Intern Med . 1988;148:2561–2568
  8. Klastersky J , Paesmans M , Rubenstein EB , et al.   The Multinational Association for Supportive Care in Cancer Risk Index (A multinational scoring system for identifying low-risk febrile neutropenic cancer patients) . J Clin Oncol . 2000;18:3038–3051
  9. Lyman GH , Kuderer NM , Djulbegovic B . A meta-analysis of granulocyte colon-stimulating factor (rH-G-CSF) to prevent febrile neutropenia in patients receiving cancer chemotherapy . Am J Med . 2002;112:406–411
  10. Vogel CL , Wojtukiewicz MZ , Carroll RR , et al.   First and subsequent cycle use of pegfilgrastim prevents febrile neutropenia in patients with breast cancer (A multicenter, double-blind, placebo-controlled phase III study) . J Clin Oncol . 2005;23:1178–1184
  11. Crawford J, Dale DC, Htoy S, et al: Myeloid growth factors in cancer treatment. NCCN Practice Guidelines, Clinical Practice Guidelines in Oncology. v.1.2005. http://www.nccn.org/professionals/physician_gls/PDF/myeloid_growth.pdf.
  12. Clark OA , Lyman G , Castro AA , et al.   Colony stimulating factors for chemotherapy induced febrile neutropenia . Cochrane Database of Systemic Reviews 2 . 2004;
  13. Maher DW , Graham JL , Green M , et al.   Filgrastim in patients with chemotherapy induced febrile neutropenia (A double blind, placebo-controlled trial) . Ann Intern Med . 1994;121:492–501
  14. Ozer H , Armitage JO , Bennett CL , et al.   2000 Update of recommendations for the use of hematopoietic colony-stimulating factors (Evidence-based, clinical practice guidelines) . J Clin Oncol . 2000;18:3558–3585
  15. Kuderer N, Cosler LE, Crawford J, et al: Cost and mortality associated with febrile neutropenia in adult cancer patients. Cancer (in press)
  16. Crawford J , Ozer H , Stoller R , et al.   Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer . N Engl J Med . 1991;325:164–170
  17. Lyman GH , Lyman CG , Sanderson RA , et al.   Decision analysis of hematopoietic growth factor use in patients receiving cancer chemotherapy . J Natl Cancer Inst . 1993;85:488–493
  18. Cosler LE , Calhoun EA , Agboola O , et al.   Effects of indirect and additional direct costs on the risk threshold for prophylaxis with colony-stimulating factors in patients at risk for severe neutropenia from cancer chemotherapy . Pharmacotherapy . 2002;24:488–489
  19. Bonadonna G , Zambetti M , Valagussa P , et al.   Adjuvant cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer (The results of 20 years of follow-up) . N Engl J Med . 1995;332:901–906
  20. Wood WC , Budman DR , Korzun AH , et al.   Dose and dose intensity of adjuvant chemotherapy for stage II, node-positive breast carcinoma . N Engl J Med . 1994;330:1253–1259
  21. Lyman GH , Dale DC , Crawford J . Incidence and predictors of low dose-intensity in adjuvant breast cancer chemotherapy (A nationwide study of community practices) . J Clin Oncol . 2003;21:4524–4531
  22. Citron ML , Berry DA , Cirrincione C , et al.   Randomized trial of dose-dense versus conventionally scheduled and sequential versus combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer (First report of intergroup trial C9741/Cancer and Leukemia Group B trial 9741) . J Clin Oncol . 2003;21:1431–1439
  23. Epstein JM , Donnelly SM , O’Byrne JM , et al.   Community experience with filgrastim in diverse nonmyeloid malignancies (an open-label phase 4 study) . J Support Oncol . 2004;2(suppl 2):54–55
  24. Ashley J , Taylor D , Houts A . The experience of chemotherapy-induced neutropenia (Quality-of-life interviews with adult cancer patients) . J Support Oncol . 2004;2(suppl 2):66–67
  25. Calhoun EA , Chang CH , Weshman EE , et al.   The impact of chemotherapy delays on quality of life in patients with cancer . Blood . 2003;(suppl):749a; (pt. 1): (abstr 2763)
  26. Ludwig H , Friz E . Anemia in cancer patients . Semin Oncol . 1998;25(suppl 7):2–6
  27. Meyer RM , Browman GP , Samosh ML , et al.   Randomized phase II comparison of standard CHOP with weekly CHOP in elderly patients with non-Hodgkin’s lymphoma . J Clin Oncol . 1995;13:2386–2393
  28. Barrett-Lee PJ , Bailey NP , O’Brien MER , et al.   Large-scale UK audit of blood transfusion requirements and anaemia in patients receiving cytotoxic chemotherapy . Br J Cancer . 2000;82:93–97
  29. Groopman JE , Itri LM . Chemotherapy-induced anemia in adults (Incidence and treatment) . J Natl Cancer Inst . 1999;91:1616–1634
  30. Henry DH , Abels RI . Recombinant human erythropoietin in the treatment of cancer and chemotherapy-induced anemia (Results of double-blind and open-label follow-up studies) . Semin Oncol . 1994;21(suppl 3):21–28
  31. Glaspy J , Bukowski R , Steinberg D , et al.   Impact of therapy with epoetin alfa on clinical outcomes in patients with non-myeloid malignancies during cancer chemotherapy in community oncology practices . J Clin Oncol . 1997;15:1218–1234
  32. Demetri GD , Kris M , Wade J , et al.  Procrit Study Group   Quality-of-life benefit in chemotherapy patients treated with epoetin alfa is independent of disease response or tumor type (Results from a prospective community study) . J Clin Oncol . 1998;16:3412–3425
  33. Gabrilove JL , Cleeland CS , Livingston RB , et al.   Clinical evaluation of once-weekly dosing of epoetin alfa in chemotherapy (Improvements in hemoglobin and quality of life are similar to three-times-weekly dosing) . J Clin Oncol . 2001;19:2875–2882
  34. Littlewood TJ , Bajetta E , Nortier JWR , et al.   Effects of eEpoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy (Results of a randomized, double-blind, placebo-controlled trial) . J Clin Oncol . 2001;19:2865–2874
  35. Quirt I , Robeson C , Lau CY , et al.   Epoetin alfa therapy increases hemoglobin levels and improves quality of life in patients with cancer-related anemia who are not receiving chemotherapy and patients with anemia who are not receiving chemotherapy . J Clin Oncol . 2001;19:4126–4134
  36. Glaspy JA , Jadeja JS , Justice G , et al.   Darbepoetin alfa given every 1 or 2 weeks alleviates anaemia associated with cancer chemotherapy . Br J Cancer . 2002;87:268–276
  37. Hedenus M , Adriansson M , Miguel JS , et al.   Efficacy and safety of darbepoetin alfa in anaemic patients with lymphoproliferative malignancies (A randomized, double-blind, placebo-controlled study) . Br J Haematol . 2003;122:394–403
  38. Vansteenkiste J , Pirker R , Massuti B , et al.   Double-blind, placebo-controlled, randomized phase trial of darbepoetin alfa in lung cancer patients receiving chemotherapy . J Natl Cancer Inst . 2002;94:1211–1220
  39. Glaspy J , Jadeja J , Justice G , et al.   A randomized, active-control, pilot trial of front-loaded dosing regimens of darbepoetin-alfa for the treatment of patients with anemia during chemotherapy for malignant disease . Cancer . 2003;97:1312–1320
  40. Smith RE , Tchekmedyian NS , Chan D , et al.   A dose- and schedule-finding study of darbepoetin alfa for the treatment of chronic anaemia of cancer . Br J Cancer . 2003;88:1851–1858
  41. Auerbach M , Ballard H , Trout JR , et al.   Intravenous iron optimizes the response to recombinant human erythropoietin in cancer patients with chemotherapy-related anemia (A multicenter, open-label, randomized trial) . J Clin Oncol . 2004;22:1301–1307
  42. Vogelzang NJ , Breitbart W , Cella D , et al.   Patient, caregiver, and oncologist perception of cancer-related fatigue (Results of a tripart assessment survey) . Semin Hematol . 1997;34(suppl 2):4–12
  43. Hillman RS , Finch CA . In: Red Cell Manual . (ed 7).. Philadelphia, PA: Davis; 1996;
  44. Glaspy J , Bukowski R , Steinberg D , et al.   Impact of therapy with epoetin alfa on clinical outcomes in patients with non-myeloid malignancies during cancer chemotherapy in community oncology practices . J Clin Oncol . 1997;15:1218–1234
  45. Gabrilove JL , Cleeland CS , Livingston RB , et al.   Clinical evaluation of once-weekly dosing of epoetin alfa in chemotherapy (Improvements in hemoglobin and quality of life are similar to three-times-weekly dosing) . J Clin Oncol . 2001;19:2875–2882
  46. Demetri GD , Kris M , Wade J , et al.  Procrit Study Group   Quality-of-life benefit in chemotherapy patients treated with epoetin alfa is independent of disease response or tumor type (Results from a prospective community study) . J Clin Oncol . 1998;16:3412–3425
  47. Crawford J , Cella D , Cleeland CS , et al.   Relationship between changes in hemoblobin level and quality of life during chemotherapy in anemic cancer patients receiving epoetin alfa therapy . Cancer . 2002;95:888–895
  48. Cella D , Kallich J , McDermott A , et al.   The longitudinal relationship of hemoglobin, fatigue and quality of life in anemic cancer patients (Results from five randomized clinical trials) . Ann Oncol . 2004;15:979–986
  49. Sheffield R , Sullivan SD , Saltiel E , et al.   Cost comparison of recombinant human erythropoietin and blood transfusion in cancer chemotherapy-induced anemia . Ann Pharmacother . 1997;31:15–22
  50. Grogan M , Thomas GM , Melamed I , et al.   The importance of hemoglobin levels during radiotherapy for carcinoma of the cervix . Cancer . 1999;86:1528–1536
  51. Brizel DM , Dodge RK , Clough RW , et al.   Oxygenation of head and neck cancer; changes during radiotherapy and impact on treatment options . Radiother Oncol . 1998;53:113–117
  52. Socinski MA , Zhang C , Herndon JE , et al.   Combine modality trials of the Cancer and Leukemia Group B in stage III non-small cell lung cancer (Analysis of factors influencing survival and toxicity) . Ann Oncol . 2004;15:1033–1041
  53. Glaser CM , Millesi W , Kornek GV , et al.   Impact of hemoglobin level and use of recombinant erythropoietin on efficacy of preoperative chemoradiation therapy for squamous cell carcinoma of the oral cavity and oropharynx . Int J Radiat Oncol Biol Phys . 2001;50:705–715
  54. Pirker R , Vansteenkiste J , Gateley J , et al.   A phase III, double-blind, placebo-controlled randomized study of novel erythropoiesis stimulating protein (NESP) in patients undergoing platinum treatment for lung cancer . Eur J Cancer . 2001;37(suppl 6):264
  55. Crawford J , Robert F , Perry M , et al.   Epoetin alfa 40,000 u once weekly maintains hemoglobin in advanced non-small cell lung cancer patients receiving first-line chemotherapy . Proc Am Soc Clin Oncol . 2003;22:628; (abstr 2527)
  56. Leyland-Jones B . Breast cancer trial with erythropoietin terminated unexpectedly . Lancet Oncol . 2003;4:459–460
  57. Henke M . Erythropoietin to treat head and neck cancer patient with anaemia undergoing radiotherapy (Randomized, double-blind, placebo-controlled trial) . Lancet . 2003;362:1255–1259
  58. Arcasoy M , Jiang X , Haroon ZA . Expression of erythropoietin receptor splice variants in human cancer . Biochem Biophys Res Comm . 2003;307:999–1007
  59. Arcasoy M , Amin K , Karayal AF . Functional significance of erythropoietin receptor expression in breast cancer . Lab Invest . 2002;82:911–918
  60. Acs G , Zhang PJ , McGarth CM , et al.   Hypoxia-inducible erythropoietin signaling in squamous dysplasia and squamous cell carcinoma of the uterine cervix and its potential role in cervical carcinogenesis and tumor progression . Am J Pathol . 2003;162:1789–1806
  61. Bohlius J , Langensiepen S , Schwarzer G , et al.   Recombinant human erythropoietin and overall survival in cancer patients (Results of a comprehensive meta-analysis) . J Natl Cancer Inst . 2005;97:489–491
  62. Blay JY , LeCesne A , Mermet C , et al.   A risk model for thrombocytopenia requiring platelet transfusion after cytotoxic chemotherapy . Blood . 1998;92:405–410
  63. Surgenor DM , Wallace EL , Hao SH , et al.   Collection and transfusion of blood in the United States, 1982-1988 . N Engl J Med . 1990;322:1646–1651
  64. Meehan KR , Matias CO , Rathore SS , et al.   Platelet transfusions (Utilization and associated costs in a tertiary care hospital) . Am J Hematol . 2000;64:251–256
  65. Schiffer CA , Anderson KC , Bennett CL . Platelet transfusion for patients with cancer (Clinical practice guidelines for the American Society of Clinical Oncology) . J Clin Oncol . 2001;19:1519–1538
  66. Rebulla P , Finazzi G , Marangoni F , et al.   The Gruppo Italiano Malattie Ematologich Maligne dell’Adulto: The threshold for prophylactic platelet transfusions in adults with acute myeloid leukemia: 10,000/mcL versus 20,000/mcL . J Clin Oncol . 1997;15:1143–1149
  67. McCullough J . Current issues with platelet transfusion in patients with cancer . Semin Hematol . 2000;37:3–10
  68. Sanz C , Freire C , Alcorta I . Platelet-specific antibodies in HLA-immunized patients receiving chronic platelet support . Transfusion . 2001;41:762–765
  69. Kuter DJ , Goodnough LT , Romo J , et al.   Thrombopoietin therapy increases platelet yields in healthy platelet donors . Blood . 2001;98:1339–1345
  70. Basser RL , Rasko JE , Clark K , et al.   Thrombopoietic effects of pegylated recombinant human megakaryocyte growth and development factor (PEG-rHuMGDF) in patients with advanced cancer . Lancet . 1998;348:1279–1281
  71. Vadhan-Raj S , Verschraegen CF , Bueso-Ramos C , et al.   Recombinant human thrombopoetin attenuates carboplatin-induced severe thrombocytopenia and the need for platelet transfusions in patients with gynecologic cancer . Ann Intern Med . 2000;132:364–368
  72. Fanucchi  , Glaspy J , Crawford J , et al.   Effects of polyethylene glycol-conjugated recombinant human megakaryocyte growth and development factor on platelet counts after chemotherapy for lung cancer . ?? N Engl J Med . 1997;336:404–409
  73. Schiffer CA , Miller K , Larson RA , et al.   A double-blind, placebo-controlled trial of pegylated recombinant human megakaryocyte growth and development factor as an adjunct to induction and consolidation therapy for patients with acute myeloid leukemia . Blood . 2000;95:2530–2535
  74. Li J , Yang C , Xia Y , et al.   Thrombocytopenia caused by the development of antibodies to thrombopoietin . Blood . 2001;98:3241–3248
  75. Tepler I , Elias L , Smith JW , et al.   A randomized placebo-controlled trial of recombinant huan interleukin-11 in cancer patients with severe thrombocytopenia due to chemotherapy . Blood . 1996;87:3607–3614
  76. Vredenburgh JJ , Hussein A , Fisher D , et al.   A randomized trial of recombinant human interleukin-11 following autologous bone marrow transplantation with peripheral blood progenitor cell support in patients with breast cancer . Biol Blood Marrow Transplant . 1998;4:134–141
  77. Cantor SB , Elting LS , Hudson DV , et al.   Pharmacoeconomic analysis of oprelvekin (recombinant human interleukin-11) for secondary prophylaxis of thrombocytopenia in solid tumor patients receiving chemotherapy . Cancer . 2003;97:3099–3106

PII: S0093-7754(05)00433-1

doi: 10.1053/j.seminoncol.2005.11.003

Seminars in Oncology
Volume 33, Issue 1 , Pages 74-85 , February 2006

Article Tools

* Image Usage & Resolution